, PHARMACOTHERAPEUTICS SUCCESS GUIDE:
2025 EXAM PREP WITH ARCANGELO &
PETERSON
📘 Verified | Detailed Rationales | 1,120 Questions | Designed for Guaranteed Clinical
Competency
Table of Contents
1. Issues for the Practitioner in Drug Therapy
2. Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
3. Impact of Drug Interactions and Adverse Events on Therapeutics
4. Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
5. Pharmacotherapy Principles in Older Adults
6. Principles of Antimicrobial Therapy
7. Pharmacogenomics
8. The Economics of Pharmacotherapeutics
9. Principles of Pharmacology in Pain Management
10. Pain Management in Opioid Use Disorder (OUD) Patients
11. Cannabis and Pain Management
12. Dermatitis
13. Bacterial, Fungal, and Viral Infections of the Skin
14. Psoriasis
15. Acne Vulgaris and Rosacea
16. Ophthalmic Disorders
17. Otitis Media and Otitis Externa
18. Hypertension
19. Hyperlipidemia
20. Chronic Stable Angina and Myocardial Infarction
,21. Heart Failure
22. Arrhythmias
23. Respiratory Infections
24. Asthma and Chronic Obstructive Pulmonary Disease
25. Gastric, Functional and Inflammatory Bowel Disorders
26. Gastroesophageal Reflux Disease and Peptic Ulcer Disease
27. Liver Diseases
28. Urinary Tract Infection
29. Prostatic Disorders and Erectile Dysfunction
30. Overactive Bladder
31. Sexually Transmitted Infections
32. Osteoarthritis and Gout
33. Osteoporosis
34. Rheumatoid Arthritis
35. Headaches
36. Seizure Disorders
37. Alzheimer’s Disease
38. Parkinson Disease
39. Major Depressive Disorder and Bipolar Disorders
40. Anxiety Disorders
41. Sleep Disorders
42. Attention Deficit Hyperactivity Disorder
43. Substance Use Disorders
44. Diabetes Mellitus
45. Thyroid and Parathyroid Disorders
46. Allergies and Allergic Reactions
47. Human Immunodeficiency Virus
,48. Organ Transplantation
49. Pharmacotherapy for Select Thromboembolic Disorders
50. Anemias
51. Immunizations
52. Smoking Cessation
53. Weight Loss
54. Contraception
55. Menopause
56. Vaginitis
, I. Prescriptive Authority and State-Specific Legal Scope
(10 questions)
1. An APRN in State X wants to prescribe a Schedule II
opioid. Which resource should she consult first?
A. DEA’s national prescribing handbook
B. State X’s Nurse Practice Act
C. Hospital formulary guidelines
D. Federal Controlled Substances Act
Answer: B
Rationale: State Nurse Practice Acts define
scope/licensure requirements; federal law sets baseline
but state law may impose additional restrictions (A, D
incomplete; C is organizational).
2. Which statement about collaborative practice
agreements (CPAs) is true?
A. CPAs override state prescribing limits.
B. CPAs are optional in “full practice” states.
C. CPAs always require direct physician supervision.
D. CPAs permit independent prescribing across all US
states.
Answer: B
Rationale: In full practice states, APPs may prescribe
independently, so CPAs aren’t required; A and D are false;
C applies in restricted states.
3. An NP relocates from State A (full practice) to State B
(restricted practice). What must she obtain before
, prescribing independently?
A. Federal DEA re-registration
B. New hospital privileges
C. Collaborative agreement with physician
D. Board certification in pharmacology
Answer: C
Rationale: Restricted states require physician CPA; DEA
registration continues but state CPA is new requirement (A
not sufficient; B irrelevant; D not required).
4. Which best describes the impact of the Federal
Comprehensive Addiction and Recovery Act (CARA) on
APP prescribing?
A. It removed APPs’ ability to prescribe buprenorphine.
B. It limited opioid prescribing to 3 days.
C. It allowed certain APPs to obtain waivers to prescribe
buprenorphine.
D. It mandated urine drug testing for all opioid
prescriptions.
Answer: C
Rationale: CARA expanded waiver eligibility to NPs/PAs for
buprenorphine; A, B, D are incorrect.
5. An APP reviews her state’s PDMP (Prescription Drug
Monitoring Program). This is primarily to:
A. Ensure formulary compliance
B. Track controlled-substance prescriptions
C. Obtain insurance preauthorization
, D. Check for food-drug interactions
Answer: B
Rationale: PDMPs monitor controlled substances to
identify misuse; A, C, D unrelated.
6. Under the federal Emergency Medical Services Act, APPs
providing care during a declared emergency can:
A. Ignore all state prescribing regulations
B. Prescribe controlled substances without DEA
registration
C. Practice under expanded interstate compacts
D. Dispense medications from national stockpiles only
Answer: C
Rationale: Emergency compacts may permit cross-state
practice; A and B are false; D is too narrow.
7. Which element is NOT typically found in a state’s
prescriptive-authority statute?
A. Required level of physician collaboration
B. Specific drugs APPs may not prescribe
C. Mandated continuing education hours
D. National formulary recommendations
Answer: D
Rationale: States regulate scope, collaboration, CE;
national formulary is organizational, not statutory.
8. A PA prescribes in a state that requires direct physician
supervision. “Direct supervision” means the physician
must:
, A. Review every chart after the encounter
B. Be physically present and immediately available
C. Sign off on prescriptions within 48 hours
D. Be co-listed on the prescription pad
Answer: B
Rationale: Direct = physician physically on-site and
available; A and C describe indirect methods; D irrelevant.
9. Which practice model best maximizes APP autonomy
where state law allows?
A. Delegated-task model
B. Supervised model
C. Independent (full practice) model
D. Protocol-driven model
Answer: C
Rationale: Full practice grants APPs independent
prescribing; others involve varying oversight.
10. When prescribing off-label in pediatrics, an APP
must ensure that:
A. Insurance will cover the cost
B. There is sufficient evidence and informed consent
C. Another provider has prescribed it first
D. It’s listed in the state Nurse Practice Act
Answer: B
Rationale: Off-label use requires evidence support and
patient/guardian consent; A, C, D are incorrect.
, II. Ethical Prescribing and Provider Accountability (10
questions)
11. Which principle supports prescribing a less
expensive generic over a brand-name drug?
A. Autonomy
B. Beneficence
C. Justice
D. Nonmaleficence
Answer: C
Rationale: Justice relates to fair distribution of resources;
B is doing good but C addresses cost equity.
12. An APP faces pressure from a pharmaceutical rep to
prescribe Drug X. Ethically she should:
A. Accept nominal gifts but comply with reps
B. Follow her clinical judgment regardless of incentives
C. Only prescribe Drug X if incentives exceed $100
D. Delegate prescribing decisions to another provider
Answer: B
Rationale: Avoid conflicts; prescribing must reflect best
patient interest; A and C violate impartiality; D abdicates
responsibility.
13. A patient requests a benzodiazepine refill despite
risk factors for misuse. Ethically, the APP should:
A. Refill and schedule follow-up in 6 months
B. Refuse refill and refer for addiction evaluation
C. Prescribe a higher dose to reduce visits
, D. Delegate decision to the supervising physician
Answer: B
Rationale: Nonmaleficence demands avoiding harm;
addiction evaluation addresses safety; A/C risky; D delays
needed care.
14. In documenting rationale for a controlled-substance
prescription, the APP demonstrates:
A. Autonomy
B. Accountability
C. Paternalism
D. Beneficence
Answer: B
Rationale: Thorough records reflect accountability; A is
choice freedom; C undermines patient involvement; D is
general good-doing.
15. Which scenario could be construed as negligent
prescribing?
A. Adjusting dose per renal function
B. Failing to check drug interactions
C. Educating patient on side effects
D. Using evidence-based guidelines
Answer: B
Rationale: Negligence = omission of standard care
(interaction check); others follow best practices.
16. When an APP prescribes teratogenic medication to a
woman of childbearing potential, she must:
2025 EXAM PREP WITH ARCANGELO &
PETERSON
📘 Verified | Detailed Rationales | 1,120 Questions | Designed for Guaranteed Clinical
Competency
Table of Contents
1. Issues for the Practitioner in Drug Therapy
2. Pharmacokinetic Basis of Therapeutics and Pharmacodynamic Principles
3. Impact of Drug Interactions and Adverse Events on Therapeutics
4. Principles of Pharmacotherapy in Pediatrics, Pregnancy and Lactation
5. Pharmacotherapy Principles in Older Adults
6. Principles of Antimicrobial Therapy
7. Pharmacogenomics
8. The Economics of Pharmacotherapeutics
9. Principles of Pharmacology in Pain Management
10. Pain Management in Opioid Use Disorder (OUD) Patients
11. Cannabis and Pain Management
12. Dermatitis
13. Bacterial, Fungal, and Viral Infections of the Skin
14. Psoriasis
15. Acne Vulgaris and Rosacea
16. Ophthalmic Disorders
17. Otitis Media and Otitis Externa
18. Hypertension
19. Hyperlipidemia
20. Chronic Stable Angina and Myocardial Infarction
,21. Heart Failure
22. Arrhythmias
23. Respiratory Infections
24. Asthma and Chronic Obstructive Pulmonary Disease
25. Gastric, Functional and Inflammatory Bowel Disorders
26. Gastroesophageal Reflux Disease and Peptic Ulcer Disease
27. Liver Diseases
28. Urinary Tract Infection
29. Prostatic Disorders and Erectile Dysfunction
30. Overactive Bladder
31. Sexually Transmitted Infections
32. Osteoarthritis and Gout
33. Osteoporosis
34. Rheumatoid Arthritis
35. Headaches
36. Seizure Disorders
37. Alzheimer’s Disease
38. Parkinson Disease
39. Major Depressive Disorder and Bipolar Disorders
40. Anxiety Disorders
41. Sleep Disorders
42. Attention Deficit Hyperactivity Disorder
43. Substance Use Disorders
44. Diabetes Mellitus
45. Thyroid and Parathyroid Disorders
46. Allergies and Allergic Reactions
47. Human Immunodeficiency Virus
,48. Organ Transplantation
49. Pharmacotherapy for Select Thromboembolic Disorders
50. Anemias
51. Immunizations
52. Smoking Cessation
53. Weight Loss
54. Contraception
55. Menopause
56. Vaginitis
, I. Prescriptive Authority and State-Specific Legal Scope
(10 questions)
1. An APRN in State X wants to prescribe a Schedule II
opioid. Which resource should she consult first?
A. DEA’s national prescribing handbook
B. State X’s Nurse Practice Act
C. Hospital formulary guidelines
D. Federal Controlled Substances Act
Answer: B
Rationale: State Nurse Practice Acts define
scope/licensure requirements; federal law sets baseline
but state law may impose additional restrictions (A, D
incomplete; C is organizational).
2. Which statement about collaborative practice
agreements (CPAs) is true?
A. CPAs override state prescribing limits.
B. CPAs are optional in “full practice” states.
C. CPAs always require direct physician supervision.
D. CPAs permit independent prescribing across all US
states.
Answer: B
Rationale: In full practice states, APPs may prescribe
independently, so CPAs aren’t required; A and D are false;
C applies in restricted states.
3. An NP relocates from State A (full practice) to State B
(restricted practice). What must she obtain before
, prescribing independently?
A. Federal DEA re-registration
B. New hospital privileges
C. Collaborative agreement with physician
D. Board certification in pharmacology
Answer: C
Rationale: Restricted states require physician CPA; DEA
registration continues but state CPA is new requirement (A
not sufficient; B irrelevant; D not required).
4. Which best describes the impact of the Federal
Comprehensive Addiction and Recovery Act (CARA) on
APP prescribing?
A. It removed APPs’ ability to prescribe buprenorphine.
B. It limited opioid prescribing to 3 days.
C. It allowed certain APPs to obtain waivers to prescribe
buprenorphine.
D. It mandated urine drug testing for all opioid
prescriptions.
Answer: C
Rationale: CARA expanded waiver eligibility to NPs/PAs for
buprenorphine; A, B, D are incorrect.
5. An APP reviews her state’s PDMP (Prescription Drug
Monitoring Program). This is primarily to:
A. Ensure formulary compliance
B. Track controlled-substance prescriptions
C. Obtain insurance preauthorization
, D. Check for food-drug interactions
Answer: B
Rationale: PDMPs monitor controlled substances to
identify misuse; A, C, D unrelated.
6. Under the federal Emergency Medical Services Act, APPs
providing care during a declared emergency can:
A. Ignore all state prescribing regulations
B. Prescribe controlled substances without DEA
registration
C. Practice under expanded interstate compacts
D. Dispense medications from national stockpiles only
Answer: C
Rationale: Emergency compacts may permit cross-state
practice; A and B are false; D is too narrow.
7. Which element is NOT typically found in a state’s
prescriptive-authority statute?
A. Required level of physician collaboration
B. Specific drugs APPs may not prescribe
C. Mandated continuing education hours
D. National formulary recommendations
Answer: D
Rationale: States regulate scope, collaboration, CE;
national formulary is organizational, not statutory.
8. A PA prescribes in a state that requires direct physician
supervision. “Direct supervision” means the physician
must:
, A. Review every chart after the encounter
B. Be physically present and immediately available
C. Sign off on prescriptions within 48 hours
D. Be co-listed on the prescription pad
Answer: B
Rationale: Direct = physician physically on-site and
available; A and C describe indirect methods; D irrelevant.
9. Which practice model best maximizes APP autonomy
where state law allows?
A. Delegated-task model
B. Supervised model
C. Independent (full practice) model
D. Protocol-driven model
Answer: C
Rationale: Full practice grants APPs independent
prescribing; others involve varying oversight.
10. When prescribing off-label in pediatrics, an APP
must ensure that:
A. Insurance will cover the cost
B. There is sufficient evidence and informed consent
C. Another provider has prescribed it first
D. It’s listed in the state Nurse Practice Act
Answer: B
Rationale: Off-label use requires evidence support and
patient/guardian consent; A, C, D are incorrect.
, II. Ethical Prescribing and Provider Accountability (10
questions)
11. Which principle supports prescribing a less
expensive generic over a brand-name drug?
A. Autonomy
B. Beneficence
C. Justice
D. Nonmaleficence
Answer: C
Rationale: Justice relates to fair distribution of resources;
B is doing good but C addresses cost equity.
12. An APP faces pressure from a pharmaceutical rep to
prescribe Drug X. Ethically she should:
A. Accept nominal gifts but comply with reps
B. Follow her clinical judgment regardless of incentives
C. Only prescribe Drug X if incentives exceed $100
D. Delegate prescribing decisions to another provider
Answer: B
Rationale: Avoid conflicts; prescribing must reflect best
patient interest; A and C violate impartiality; D abdicates
responsibility.
13. A patient requests a benzodiazepine refill despite
risk factors for misuse. Ethically, the APP should:
A. Refill and schedule follow-up in 6 months
B. Refuse refill and refer for addiction evaluation
C. Prescribe a higher dose to reduce visits
, D. Delegate decision to the supervising physician
Answer: B
Rationale: Nonmaleficence demands avoiding harm;
addiction evaluation addresses safety; A/C risky; D delays
needed care.
14. In documenting rationale for a controlled-substance
prescription, the APP demonstrates:
A. Autonomy
B. Accountability
C. Paternalism
D. Beneficence
Answer: B
Rationale: Thorough records reflect accountability; A is
choice freedom; C undermines patient involvement; D is
general good-doing.
15. Which scenario could be construed as negligent
prescribing?
A. Adjusting dose per renal function
B. Failing to check drug interactions
C. Educating patient on side effects
D. Using evidence-based guidelines
Answer: B
Rationale: Negligence = omission of standard care
(interaction check); others follow best practices.
16. When an APP prescribes teratogenic medication to a
woman of childbearing potential, she must:
